BCR-ABL1 Kinase Domain Mutation Analysis (NGS) in Dubai, UAE | 2000 AED

Executive Summary & Core Metrics

✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited NGS Processing (Cert: INT/EGQ/2509DA/3139).
✓ Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection for peripheral blood (available daily 8 AM – 11 PM); bone marrow aspirate requires hospital extraction only.
✓ Clinical Guidance: Telephonic post-test clinical guidance in result interpretation by DHA-licensed specialists, overseen by Consultant Medical Geneticist (DHA ID 9294403).
✓ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

BCR-ABL1 kinase domain mutation analysis is a pivotal next-generation sequencing (NGS) test for identifying resistance mutations in patients with chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitor therapy. This advanced genomic profiling helps oncologists select second- or third-line TKIs to overcome drug resistance, ensuring personalized treatment and improved outcomes.

Feature	Our Test (NGS)	Closest Alternative (Sanger Sequencing)
Methodology	Next-Generation Sequencing (NGS) with unique molecular identifiers	Sanger sequencing
Sensitivity	>99.9% for mutations down to 1% variant allele fraction	15–20% variant allele fraction
Turnaround Time	14–21 days	7–10 days
Price	2000 AED	Similar price range

Physician Insight & Safety Protocols

“Interpreting BCR-ABL1 mutation results requires a multidisciplinary approach; a mutation detected does not always demand an immediate therapy change. I strongly advise discussing the report with your treating hematologist-oncologist to correlate with clinical and molecular response milestones.” — Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA License No. 9294403.

Advisory – Medication Do Not Discontinue Without Consultation

Do not stop or modify your tyrosine kinase inhibitor (TKI) therapy without explicit instruction from your prescribing hematologist. Abrupt cessation can lead to rapid disease progression.

Safety Exclusion Criteria & Emergency Red Flags

Exclusion for Bone Marrow Aspirate: Severe coagulopathy (INR >1.5, platelets <50,000/µL), active infection at aspiration site, or patient unable to lie prone. Peripheral blood collection is safe for most patients and preferred for mutation analysis when clinically adequate.
Emergency Red Flags After Sample Collection: Seek immediate medical attention if you experience sudden severe bone pain, fever with neutropenia (temperature >38.3°C and ANC <500 cells/µL), or neurological symptoms suggestive of blast crisis.
Pre-test Information: A valid DHA-licensed physician’s prescription is required. No specific drug washout is needed for this test; however, for optimal sensitivity, peripheral blood should be drawn immediately before the next scheduled TKI dose (if applicable). Bone marrow aspirate must be scheduled at our partner hospital under sterile conditions.

Patient FAQ & Clinical Guidance

1. What does a BCR-ABL1 kinase domain mutation test detect?

This test identifies specific genetic mutations within the BCR-ABL1 kinase domain that can cause resistance to tyrosine kinase inhibitors, guiding precise CML treatment adjustments.

2. How is the sample collected, and is it painful?

The preferred sample is peripheral blood (standard venipuncture, minimal discomfort). If bone marrow aspirate is required, it is performed under local anesthesia in a hospital setting to minimize pain. The choice of sample is determined by your physician.

3. How long does it take to get results, and what do I do after?

Results are typically available within 14–21 days. Upon receiving the report, schedule a telephonic clinical guidance session with our DHA-licensed consultant medical geneticist for a comprehensive interpretation and next steps.

UAE Regulatory & Data Privacy Adherence

UAE Healthcare Compliance: This service strictly adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. All testing is performed under DHA facility license No. 1143.

Clinical & Logistical Metadata

Test Name	BCR-ABL1 Kinase Domain Mutation Analysis (NGS)
Price (AED)	2000 AED
Turnaround Time	14–21 days
Sample Type / Matrix	Peripheral blood (preferred) or bone marrow aspirate
Methodology Used	Next-Generation Sequencing (NGS) with unique molecular identifiers
ICD-10-CM Code	C92.1
LOINC Code	30504-1
DHA Facility License & Laboratory Address	License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE